This site is intended for Healthcare professionals only.

Zydus Cadila gets final approval from USFDA for Hepatitis B tablets


Zydus Cadila gets final approval from USFDA for Hepatitis B tablets

AHMEDABAD: Cadila Healthcare Ltd (Zydus Cadila) said here on Tuesday that it has received the final approval from the USFDA to market Entecavir tablets in the strengths of 0.5 mg and 1 mg.

The drug is used in the treatment of Hepatitis B virus infection and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad, the company said in a release here.

The estimated sale for Entecavir tablets is $ 166.3 million per annum.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.



Source: PTI
0 comment(s) on Zydus Cadila gets final approval from USFDA for Hepatitis B tablets

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted